Palatin Technologies (NYSEAMERICAN:PTN) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.19, Morningstar.com reports. The company had revenue of $10.61 million during the quarter. Palatin Technologies had a return on equity of 10,489.06% and a net margin of 39.36%. During the same quarter last year, the firm posted ($0.06) earnings per share.
Shares of Palatin Technologies (NYSEAMERICAN PTN) traded up $0.03 during trading hours on Tuesday, hitting $0.92. The company had a trading volume of 495,741 shares, compared to its average volume of 1,211,004. Palatin Technologies has a 52 week low of $0.29 and a 52 week high of $1.05. The company has a market cap of $174.44, a P/E ratio of 17.80 and a beta of 1.82.
A number of research analysts recently issued reports on the company. Canaccord Genuity set a $6.00 price objective on Palatin Technologies and gave the company a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research downgraded Palatin Technologies from a “buy” rating to a “strong sell” rating in a research note on Wednesday, November 1st. Finally, Roth Capital set a $2.00 price objective on Palatin Technologies and gave the company a “buy” rating in a research note on Sunday, October 29th.
TRADEMARK VIOLATION WARNING: “Palatin Technologies (PTN) Posts Earnings Results” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/13/palatin-technologies-ptn-posts-earnings-results.html.
About Palatin Technologies
Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.